Rheumatoid arthritis (RA) is one of the most common types of characters in the form. It is a systemic, chronic, progressive disorder that affects approximately, sia, two million Americans.
Although preferably attacks the joints, it can affect other body systems. These areas include, lungs, heart, skin, bone-marrow ääreishermoston, and eyes.
Early diagnosis is the key. In the case of suspicion of RA, the patient must be referred to in the rheumatologist (arthritis specialist) as soon as possible.
RA therapy, the current goal is to work with and control of the disease before the joint damage has occurred. When the diagnosis is established, an aggressive treatment should start DMARDS. These DMARDS, are usually the standard "old school" such as "the new school with DMARDS methotrexate" combination of DMARDS, called biologics (BDs). These latter drugs are proteins, which are used to focus the immune abnormalities specific to the father of the family.
This approach makes it possible to obtain a RA saw the withdrawal of the majority of patients, into account.
BDs are very complex proteins, which are much different compared to the biologic drug development process of the standard. Unlike the standard BDs is made of drugs, food proteins, antibodies or antibody. Because of this, they are very expensive, costing the edge condition, 20 000 a year in the neighborhood.
However, because the BDs are such precise "laser-targeted" weapons, they are very effective. And it is estimated that about 40% or more of patients with moderate to severe rheumatoid, take these products.
Recently, although a number of factors, including the patent expiration date and health care settings have paved the way for a "Biosimilaari" in the development of the BDs. These are essentially a generic version of the BDs, it is a good news. The Bad news is that, in the absence of the protein in the manufacture of biologic drugs is so complex, the price is expected to drop as much use of biosimilars.
Estimates vary from 60-90% of the current price, which is part of the biologic biosimilars. Cheaper but not at lower prices.
The second question is, how good they are. Because of the manufacturing process is so complex can be significant variation, so that the biosimilars may not work the same way as the original. They may also have unexpected side effects that differ from the original drugs.
In addition, the continuation of the investigation, the development of different systems for the operation of the other BDs, is expected to create a more competitive business environment. An example of some of the new oral BDs, which are expected to have a significant impact on the development of the RA development activities.
Nathan Wei, MD, FACP, FACR is a rheumatologist and the arthritis treatment Center-http://www.arthritistreatmentcenter.com/. He is a former Assistant Professor of medicine, University of Maryland, University of, school of medicine and consultant to the health of the plants. For more information: http://www.arthritis-treatment-and-relief.com/arthritis-treatment.html
Tidak ada komentar:
Posting Komentar